Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543504 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab in Multiple Phase I Combinations
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 343
- Enrollment target
NCT00543504: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00543504 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 343 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (472% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543504, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 343 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab and lapatinib. The safety and effectiveness of these drug combinations will also be studied.
Primary Outcome
MTD defined by Dose Limiting Toxicity in first 28 day cycle (induction phase)
Interventions
- DRUG Trastuzumab
- DRUG Bevacizumab
- DRUG Sorafenib
- DRUG Erlotinib
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2007-10-10 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 1 |
What the finished NCT00543504 record still lists
NCT00543504 is an interventional study that assigns participants to a tested intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (472% higher).
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00543504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00543504 about?
NCT00543504 is a clinical study titled "Bevacizumab in Multiple Phase I Combinations". The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab...
What is the current status of trial NCT00543504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 343 participants. The study started on 2007-10-10. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT00543504?
The interventions under investigation include: Trastuzumab (DRUG), Bevacizumab (DRUG), Sorafenib (DRUG), Erlotinib (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00543504?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00543504's enrollment target sits among peer trials
343 103rd of 2000 higher than 1,898 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI